CoChat

Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals

Open access
Hua, Xue, Lee, Suh, Hibar, Derrek P., Yanovsky, Igor, Leow, Alex D., Toga, Arthur W., Jack, Clifford R., Bernstein, Matt A., Reiman, Eric M., Harvey, Danielle J., Kornak, John, Schuff, Norbert, Alexander, Gene E., Weiner, Michael W., Thompson, Paul M. · 2010 · NeuroImage
Cited by 85

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Neuroimaging centers and pharmaceutical companies are working together to evaluate treatments that might slow the progression of Alzheimer’s disease (AD), a common but devastating late-life neuropathology. Recently, automated brain mapping methods, such as tensor-based morphometry (TBM) of structural MRI, have outperformed cognitive measures in their precision and power to track disease progression, greatly reducing sample size estimates for drug trials. In the largest TBM study to date, we studied how sample size estimates for tracking structural brain changes depend on the time interval between the scans (6–24 months). We analyzed 1309 brain scans from 91 probable AD patients (age at baseline: 75.4±7.5 years) and 189 individuals with mild cognitive impairment (MCI; 74.6±7.1 years), scanned at baseline, 6, 12, 18, and 24 months. Statistical maps revealed 3D patterns of brain atrophy at each follow-up scan relative to the baseline; numerical summaries were used to quantify temporal lobe atrophy within a statistically-defined region-of-interest. Power analyses revealed superior sample size estimates over traditional clinical measures. Only 80, 46, and 39 AD patients were required for a hypothetical clinical trial, at 6, 12, and 24 months respectively, to detect a 25% reduction in average change using a two-sided test (α=0.05, power=80%). Correspondingly, 106, 79, and 67 subjects were needed for an equivalent MCI trial aiming for earlier intervention. A 24-month trial provides most power, except when patient attrition exceeds 15–16%/year, in which case a 12-month trial is optimal. These statistics may facilitate clinical trial design using voxel-based brain mapping methods such as TBM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2010.01.104

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 85

Metadata

Authors
Hua, X., Lee, S., Hibar, D. P., Yanovsky, I., Leow, A. D., Toga, A. W., Jack, C. R., Bernstein, M. A., Reiman, E. M., Harvey, D. J., Kornak, J., Schuff, N., Alexander, G. E., Weiner, M. W., & Thompson, P. M.
Venue
NeuroImage
Publisher
Elsevier BV
Published
2010-05
Volume
51
Issue
1
Pages
63-75
ISSN
1053-8119 (ISSN-L)
OpenAlex
W1973142739
Cited by
85
References
33
FWCI
5.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. https://app.cochat.ai/papers/10.1016/j.neuroimage.2010.01.104
The paper
Hua, X., Lee, S., Hibar, D. P., Yanovsky, I., Leow, A. D., Toga, A. W., Jack, C. R., Bernstein, M. A., Reiman, E. M., Harvey, D. J., Kornak, J., Schuff, N., Alexander, G. E., Weiner, M. W., & Thompson, P. M. (2010). Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. NeuroImage. https://doi.org/10.1016/j.neuroimage.2010.01.104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.